PTPN11 and neoplasm: The combination of SHP2 and KRAS G12C inhibition induced favorable but tumor site-specific changes in the immune microenvironment, increasing CD8 + T cells, decreasing myeloid suppressor cells, and sensitizing tumors to PD-1 blockade [146].